Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00462
|
|||||
| Drug Name |
Olanzapine
|
|||||
| Synonyms |
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10 H-thieno[2,3-b ] [1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; ALKS-7921; Eli Lilly brand of olanzapine; KS-1090; LY 170053; LY-170052; LY-170053; Lanzac; Lilly brand of olanzapine; Midax; Olansek; Olanzapina; Olanzapine (JAN/USAN/INN); Olanzapine (OLA); Olanzapine [USAN:INN]; Olanzapinum; Olzapin (TN); Rexapin (TN); Symbyax; Zalasta; Zalasta (TN); Zolafren (TN); Zydis; Zydis (TN); Zyprexa; Zyprexa (TN); Zyprexa Intramuscular; Zyprexa Velotab; Zyprexa Zydis
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11:6A20] | Approved | [1] | |||
| Bipolar disorder [ICD11:6A60-6A61] | Approved | [1] | ||||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H20N4S
|
|||||
| Canonical SMILES |
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
|
|||||
| InChI |
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
|
|||||
| InChIKey |
KVWDHTXUZHCGIO-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 132539-06-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 312.4 | Topological Polar Surface Area | 59.1 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
2.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103195217
,103950390
,104253651
,104306829
,11528747
,12014657
,14923451
,25819934
,26612730
,26719852
,26750094
,29215187
,29215188
,29223674
,42684855
,46386668
,46507666
,48416347
,49665994
,49666419
,49681733
,49830782
,5025348
,53788662
,56310909
,56312010
,56312820
,56352944
,57288797
,57322337
,591970
,77029366
,7847520
,7980183
,81092909
,816938
,85174531
,85209215
,85213702
,85753333
,89736112
,92307994
,92308375
,92308920
,92712529
,93166490
,93167156
,93618268
,9530
,99637141
|
|||||
| ChEBI ID |
ChEBI:7735
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km =8.3 microM | Baculovirus-infected insect cells-MDR1 | [3] | |
| References | ||||||
| 1 | Olanzapine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
| 3 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.